Literature DB >> 31933287

Powered by Open Innovation: Opportunities and Challenges in the Pharma Sector.

Maria Angeles Martinez-Grau1, Maria Alvim-Gaston2.   

Abstract

The value of innovation in medicines is clear. Despite all of the progress in the twenty-first century, there are still many unmet medical needs and opportunities to improve healthcare. The challenges for pharmaceutical companies include ways in which to stay competitive and flexible in an environment of constant knowledge growth and increasingly sophisticated technologies, and ways to generate sufficient revenues to sustain their own growth. To that end, pharmaceutical companies are compelled to adapt different business models in the face of new challenges. The industry is plagued with long research and development (R&D) cycles and low success rates for innovative treatments; something has to change. The need to collaborate externally across the process of discovery, development, manufacturing and commercialization is a must. Furthermore, collaborations have increased in frequency and scope, expanding the opportunities to access global scientific talent in academia, research institutes and biotechnology companies. Despite the perception that pharma companies are 'closed' or tightly controlled industries, open innovation is already well established in the pharmaceutical sector and used to supplement R&D in the process of bringing new medicines for patients faster, and at a lower cost. Over the years, each pharma company has tailored the open-innovation concept to develop its own model based on particular needs and offerings. Independently of the model, the creation of successful partnerships in external innovation requires reaching out and connecting beyond the traditional organizational boundaries. Substantial internal cultural changes are required to implement open-innovation strategies that should co-exist without competing with the traditional ways of operating. Major changes bring challenges but create multiple opportunities for scientists and organizations. High-quality drug discovery requires continuous learning and an open way of thinking to adopt novel operational models and to implement efficient collaborations.

Entities:  

Mesh:

Year:  2019        PMID: 31933287     DOI: 10.1007/s40290-019-00280-5

Source DB:  PubMed          Journal:  Pharmaceut Med        ISSN: 1178-2595


  25 in total

Review 1.  How to improve R&D productivity: the pharmaceutical industry's grand challenge.

Authors:  Steven M Paul; Daniel S Mytelka; Christopher T Dunwiddie; Charles C Persinger; Bernard H Munos; Stacy R Lindborg; Aaron L Schacht
Journal:  Nat Rev Drug Discov       Date:  2010-02-19       Impact factor: 84.694

2.  Open innovation networks between academia and industry: an imperative for breakthrough therapies.

Authors:  Teri Melese; Salima M Lin; Julia L Chang; Neal H Cohen
Journal:  Nat Med       Date:  2009-05       Impact factor: 53.440

Review 3.  Drug discovery: new models for industry-academic partnerships.

Authors:  Cathy J Tralau-Stewart; Colin A Wyatt; Dominique E Kleyn; Alex Ayad
Journal:  Drug Discov Today       Date:  2008-11-21       Impact factor: 7.851

Review 4.  Neoclassic drug discovery: the case for lead generation using phenotypic and functional approaches.

Authors:  Jonathan A Lee; Ellen L Berg
Journal:  J Biomol Screen       Date:  2013-09-30

Review 5.  A decade of innovation in pharmaceutical R&D: the Chorus model.

Authors:  Paul K Owens; Eyas Raddad; Jeffrey W Miller; John R Stille; Kenneth G Olovich; Neil V Smith; Rosie S Jones; Joel C Scherer
Journal:  Nat Rev Drug Discov       Date:  2014-12-15       Impact factor: 84.694

Review 6.  Measuring the effectiveness and impact of an open innovation platform.

Authors:  Glenn P Carroll; Sanjay Srivastava; Adam S Volini; Marta M Piñeiro-Núñez; Tatiana Vetman
Journal:  Drug Discov Today       Date:  2017-01-27       Impact factor: 7.851

7.  Drug Discovery: Collaborations between Contract Research Organizations and the Pharmaceutical Industry.

Authors:  Victoria A Steadman
Journal:  ACS Med Chem Lett       Date:  2018-06-04       Impact factor: 4.345

8.  A new chapter in innovation.

Authors:  David Holmes
Journal:  Nature       Date:  2016-05-12       Impact factor: 49.962

Review 9.  Open innovation and external sources of innovation. An opportunity to fuel the R&D pipeline and enhance decision making?

Authors:  Alexander Schuhmacher; Oliver Gassmann; Nigel McCracken; Markus Hinder
Journal:  J Transl Med       Date:  2018-05-08       Impact factor: 5.531

10.  Michael J. Fox Foundation LRRK2 Consortium: geographical differences in returning genetic research data to study participants.

Authors:  Roy N Alcalay; Jan Aasly; Daniela Berg; Susan Bressman; Alexis Brice; Kathrin Brockmann; Piu Chan; Lorraine Clark; Florence Cormier; Jean-Christophe Corvol; Alexandra Durr; Maurizio Facheris; Matthew Farrer; Tatiana M Foroud; Thomas Gasser; Nir Giladi; Cheryl Halter; Anthony Lang; J William Langston; Connie Marras; Jose-Felix Marti-Masso; Javier Ruiz Martinez; Helen Mejia-Santana; Anat Mirelman; Claustre Pont-Sunyer; Avi Orr-Urtreger; Deborah Raymond; Rachel Saunders-Pullman; Birgitt Schüle; Caroline Tanner; Eduardo Tolosa; Alison Urkowitz; Dolores Vilas; Adina Wise; Karen Marder
Journal:  Genet Med       Date:  2014-08       Impact factor: 8.822

View more
  2 in total

Review 1.  Crowdsourcing and open innovation in drug discovery: recent contributions and future directions.

Authors:  David C Thompson; Jörg Bentzien
Journal:  Drug Discov Today       Date:  2020-10-02       Impact factor: 7.851

Review 2.  Antileishmanial Drug Discovery and Development: Time to Reset the Model?

Authors:  Ana Isabel Olías-Molero; Concepción de la Fuente; Montserrat Cuquerella; Juan J Torrado; José M Alunda
Journal:  Microorganisms       Date:  2021-12-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.